# Patent Law

Prof. Roger Ford
Wednesday, April 27, 2016
Class 25 — Patent misuse and antitrust

Recap

### Recap

- → Inventorship
- → Inequitable conduct
- → Continuation practice and prosecution laches

Today's agenda

## Today's agenda

- $\rightarrow$  Background
- → Tying arrangements
- → Patent exhaustion
- $\rightarrow$  Reverse-payment settlements

### Background

- → Patents and antitrust law are in tension
  - Antitrust law is designed to encourage competition
  - Patent law is designed to suppress competition in limited circumstances
  - So the law tries to limit the scope of patent rights to "legitimate" exercises

- → The basic patent-misuse theory
  - Patents provide market power
  - Market power can be abused
  - If you use your patent monopoly to extend it beyond what you have legitimate rights to, that's an abuse of your patent rights

### Background

- → Ten seconds of antitrust law
  - Sherman Act § 1: Contracts "in restraint of trade" are illegal
  - Sherman Act § 2: Efforts to "monopolize" are illegal
  - Clayton Act § 3: "Tying" is illegal if it lessens competition

- → The problems:
  - · Every contract restrains trade
  - Every effort to sell products or increase market share is an effort to monopolize in some sense
  - It's hard to know what lessens competition

### Background

- → The solutions:
  - Antitrust law is essentially common law
  - Some practices are "per se illegal," when there's no legitimate reason to permit them
  - Most practices are subject to the "rule of reason," under which the plaintiff has to prove the practice is anticompetitive

- → So the big question, then, is when you go beyond the legitimate scope of your patent right
  - Fraudulently acquired patents
  - Sham litigation
  - Trying to extend the patent term
  - Assessing royalties on nonpatented products

# Tying arrangements

### Tying arrangements

- → Tying: Only selling one good if the buyer also buys another good
  - Example: "I will only sell you a left shoe if you also buy the right shoe"
- → For a long time, tying arrangements were almost always seen as problematic
- → That has changed in the last few decades: 1988 amendments; changed views on economic issues

#### (post-AIA) 35 U.S.C. § 271 — Infringement of patent

\* \* \*

- (d) No patent owner otherwise entitled to relief for infringement or contributory infringement of a patent shall be denied relief or deemed guilty of misuse or illegal extension of the patent right by reason of his having done one or more of the following:
  - (1) derived revenue from acts which if performed by another without his consent would constitute contributory infringement of the patent;
  - (2) licensed or authorized another to perform acts which if performed without his consent would constitute contributory infringement of the patent;
  - (3) sought to enforce his patent rights against infringement or contributory infringement;
  - (4) refused to license or use any rights to the patent; or
  - (5) **conditioned the license** of any rights to the patent **or the sale of the patented product on** the acquisition of a license to rights in another patent or **purchase of a separate product**, unless, in view of the circumstances, the patent owner has **market power in the relevant market for the patent or patented product** on which the license or sale is conditioned. \* \* \*

## Tying arrangements

- → The innocent story: tying gives the monopolist no competitive advantage
  - Example: The marginal cost of shoes is \$10 per shoe; consumers value them at \$100 per pair
  - A monopolist in left shoes will sell the pair for \$100 – or the left shoe for \$90
  - This is the case whenever the two products are sold in <u>fixed ratios</u>

### Tying arrangements

- → The not-so-innocent story: tying can matter when the two goods are not sold in fixed ratios
  - Examples: printers and paper; razors and blades
  - These tying arrangements can be anticompetitive or not

## Tying arrangements

- → The not-so-innocent story, part II: tying can be strategic
  - Branding
  - Quality control
  - Marginal returns
  - Supply chain

### Tying arrangements

- → In antitrust law, tying is subject to the rule of reason
- → Historically, in patent law it was per se illegal

- → The tying arrangement
  - Patented: print head for barcode printers
  - Unpatented: ink

- $\rightarrow$  The concern:
  - Will Illinois Tool Works be able to <u>leverage</u> its print-head monopoly into an ink monopoly?
- → Holding?

- → The concern:
  - Will Illinois Tool Works be able to <u>leverage</u> its print-head monopoly into an ink monopoly?
- → Holding?
  - We don't actually know if Illinois Tool Works has market power in print heads
  - Patents aren't enough to infer market power
  - So we apply the rule of reason

→ How would a patent holder not have market power?

- → How would a patent holder not have market power?
  - The traditional antitrust concern: monopoly power over a <u>market</u>
  - · Patents don't necessarily define a market
  - Many patents compete with other patents to solve a problem
  - So if you don't want to use Illinois Tool Works ink, don't buy an Illinois Tool Works print head

→ <u>Timing problem</u>: Once you buy one product, you're locking yourself into the tied product

- → <u>Timing problem</u>: Once you buy one product, you're locking yourself into the tied product
  - Sometimes you can consider this when you buy the first product
  - Otherwise, this would factor into the rule-of-reason analysis

→ So why do companies demand tying arrangements, <u>other</u> than for anticompetitive purposes?

- → So why do companies demand tying arrangements, <u>other</u> than for anticompetitive purposes?
  - Metering rationale: Price discrimination against users who use more capacity
  - Quality rationale: A user who uses low-quality inputs might harm the reputation of the maker

### Patent pools

- → Another form of tying: patent pools
  - Philips and Sony had competing patents on CD players
  - Eventually they cooperated to form one standard, the "Orange Book" standard, that used Philips' patents
  - Third-party makers of CD players could only license the patents if they licensed the complete pool, including the (useless)
     Sony patents

### Patent pools

- → Princo Corp. v. ITC
- → Princo's argument: Bundling Sony's and Philips' patents is patent misuse
- → Court: It might be an antitrust violation, but it's not patent misuse
  - Patent misuse is the leveraging of patent rights to "impose over-broad conditions ... that are not within the reach of the [patent] monopoly"

### Patent pools

- → DOJ / FTC review of patent pools: Generally okay, with <u>safeguards</u>
  - · Only standards-essential patents
  - RAND licensing terms
  - Royalties based on actual use
  - Licenses available in- or outside pool
  - Freedom to develop alternative tech

Patent exhaustion

### Patent exhaustion

- → Basic theory: Once you have sold a patented product, you can't control what happens downstream
  - Similar to the first-sale doctrine in copyright law
  - This is why, when you buy a car, you don't have to get licenses for all the patents that cover the parts

### Patent exhaustion

- → Examples:
  - Resale restrictions
  - Reuse restrictions
  - · Repair restrictions

- → The license arrangement:
  - Intel makes microprocessors
  - LG owns patents on (common) methods and systems for using microprocessors in connection with other components (memory)
  - LG licenses its patents to Intel, but only for use with Intel memory
  - Intel sells microprocessors to others

- → Three questions:
  - Does exhaustion extend to method patents?
  - Does exhaustion extend to products that don't embody the complete patent?
  - Is exhaustion avoided by the terms of the Intel-LG license?

→ Does exhaustion extend to method patents?

- → Does exhaustion extend to method patents?
  - Sure, why not?

→ Does exhaustion extend to products that don't embody the complete patent?

- → Does exhaustion extend to products that don't embody the complete patent?
  - Yes
  - Otherwise, it would be easy to get around exhaustion – just sell a product that contains all but one element
  - Sort of similar to patentable subject matter

     we're looking to the "core" of the patent
     claim

→ Is exhaustion avoided by the terms of the Intel-LG license?

- → Is exhaustion avoided by the terms of the Intel-LG license?
  - No
  - Exhaustion is triggered only by a permitted sale, but Intel was explicitly permitted to sell the products (M&D 1207)

- → So couldn't LG just have restricted Intel's ability to sell the parts for use with non-Intel memory?
  - Yup
  - But Intel has a <u>lot</u> of bargaining power
  - LG has less

### Quanta Computer v. LG

→ Does it make economic sense for LG to separately license Intel and other computer makers?

- → Does it make economic sense for LG to separately license Intel and other computer makers?
  - Maybe
  - Intel might have little information about downstream users, so it'd be easier to go after them directly
  - BUT, each computer presumably uses one microprocessor — Intel has good volume information, at least!

Reverse-payment settlements

### Hatch-Waxman Act

- → Grand bargain between branded drug manufacturers and generic manufacturers
  - Branded makers: Longer patent terms
  - Generic makers: Can file ANDAs (abbreviated new drug applications)
  - Cost to develop generic drug: \$millions, not \$billions

### Hatch-Waxman Act

#### → ANDAs:

- Branded maker must list all patents applicable to a drug in the Orange Book
- Generic maker must show drugs are bioequivalents
- Generic maker must assert that all listed patents have expired, are not infringed, or are invalid

### Hatch-Waxman Act

#### → ANDAs:

- If generic maker asserts patents are invalid or not infringed (Paragraph IV), filing ANDA is technical infringement that allows patent holder to sue
- Court then determines if patent would be invalid or not infringed
- Only remedy: declaratory judgment that lets generic maker enter the market

### Hatch-Waxman Act

#### → ANDAs:

 First generic to file a Paragraph IV certification gets a 180-day period of generic exclusivity if it can show the patents are invalid or not infringed

# Reverse-payment settlements

- → Common scenario in pharma cases:
  - Branded maker has patent that expires in 2020
  - Generic maker asserts the patent is invalid
  - Branded maker sues Generic maker under the Hatch-Waxman Act
  - Parties settle: Generic agrees not to enter until 2020; Branded agrees to pay Generic money

# Reverse-payment settlements

- → Various theories:
  - These agreements are per se illegal as restraints on competition
  - These agreements are per se legal because patents are legal monopolies
  - These agreements can be procompetitive or anticompetitive rule-of-reason analysis

### FTC v. Actavis (2013)

- → Supreme Court: these agreements are subject to rule-of-reason antitrust analysis
  - Not immunized by existence of a patent – the patent might be invalid
  - Settlements are favored, but reversepayment settlements have troubling effects on competition

Next time

### Next time

 $\rightarrow$  There is no next time.

